Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133096 | 0.92 | PTPN2 (0.43) | PTPN2PTPN1EPHX1UTS2RCA12 | |
| SCHEMBL2133483 | 0.92 | MCHR1 (0.44) | CYP2D6MCHR1 | |
| SCHEMBL2731955 | 0.92 | MCHR1 (0.44) | CYP2D6MCHR1 | |
| SCHEMBL2722729 | 0.91 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2130422 | 0.91 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2131092 | 0.90 | CCR2 (0.45) | CYP2D6MCHR1MGLL | |
| SCHEMBL2722933 | 0.90 | CCR2 (0.45) | CYP2D6MCHR1MGLL | |
| SCHEMBL2132137 | 0.88 | MEN1 (0.48) | EPHX1UTS2RCA12CA1CA2 | |
| SCHEMBL2720366 | 0.86 | CCR2 (0.45) | EPHX1UTS2RCA12CA1CA2 | |
| SCHEMBL2131818 | 0.86 | CCR2 (0.45) | EPHX1UTS2RCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | claimed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | claimed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | claimed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | claimed |
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | disclosed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | disclosed |
| EP-2630139-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-28 | — | — | EP | disclosed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054721-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICAL NV (BE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | PTPN2 1186/4885PTPN1 982/4885EPHX1 846/4885 |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | PTPN2 1186/4885PTPN1 982/4885EPHX1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.